Comparative clinical study between inhalated zanamivir and laninamivir in pediatric patients with influenza
Not Applicable
- Conditions
- influenza
- Registration Number
- JPRN-UMIN000007562
- Lead Sponsor
- Hokkaido University Hospital, Dept. of pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
Not provided
Exclusion Criteria
patients judged as inadequate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method achievement of body temperature (less than 37.5 degree) after inhalated medicine
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate zanamivir and laninamivir in inhibiting influenza viral neuraminidase in pediatric populations?
How does the efficacy of inhaled zanamivir compare to laninamivir in reducing influenza A/B viral shedding in children under 12 years old?
Which biomarkers (e.g., cytokine profiles, viral load kinetics) predict treatment response to neuraminidase inhibitors in pediatric influenza trials?
What adverse events were reported in the Hokkaido University observational study comparing zanamivir and laninamivir in pediatric patients?
Are there clinical studies evaluating laninamivir's role in combination with baloxavir marboxil for influenza treatment in children?